Praxis Medicines is a CNS-focused precision neuroscience biopharmaceutical company that discovers and develops therapies for neurological disorders characterized by excitation-inhibition imbalance, leveraging genetic insights from epilepsy research. The company operates two proprietary platforms: Cerebrum, a small-molecule platform targeting neuronal excitability, and Solidus, an antisense oligonucleotide platform for precision medicine discovery. Its pipeline includes multiple clinical-stage candidates targeting essential tremor, developmental and epileptic encephalopathies, and common epilepsies, addressing large patient populations with significant unmet medical needs and limited treatment options. The company generates no current product revenues and relies on third-party contract manufacturers; revenue will depend on regulatory approval and market adoption of its pipeline candidates.